Product image of Metlinka (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metlinka

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metlinka (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metlinka, are a Biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. The combination lowers hepatic glucose production, enhances insulin sensitivity, and increases incretin activity, thereby improving glycemic control in adult patients with type 2 diabetes mellitus.

GNH India supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antidiabetic medicines and supporting therapeutic programs through consistent supply chains and regulatory compliance.

Manufacturer / TM Owner

Swyssi Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metlinka is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c when used alone.
  • Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to other oral antidiabetics or insulin.
  • Type 2 diabetes mellitus (renal impairment): provides glucose lowering with reduced risk of hypoglycaemia in patients with mild to moderate renal dysfunction.

How It Works

  • Metlinka combines metformin, which inhibits mitochondrial respiratory chain complex I to reduce hepatic gluconeogenesis and increase peripheral insulin sensitivity, with sitagliptin, a selective inhibitor of dipeptidyl peptidase‑4 that prevents degradation of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins enhance glucose‑dependent insulin secretion and suppress glucagon release, resulting in complementary reductions in blood glucose levels.

Side Effects

Metlinka may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort (nausea, abdominal pain, diarrhea)
  • Headache
  • Dizziness

Serious or Rare Side Effects

  • Lactic acidosis (rare but life‑threatening)
  • Severe hypoglycaemia, especially when combined with insulin or sulfonylureas
  • Acute pancreatitis or severe skin reactions (e.g., Stevens‑Johnson syndrome)

Precautions & Warnings

Metlinka requires careful clinical assessment before and during therapy.

  • Renal function assessment: evaluate baseline eGFR and monitor periodically.
  • Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment.
  • Hypoglycaemia monitoring: caution when used with insulin or sulfonylureas.
  • Pregnancy and lactation: prescribe only if potential benefit outweighs risk.
  • Drug interaction review: assess concomitant medications for possible interactions.
  • Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Avoid Interactions

Metlinka can interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

  • Concomitant use with phenformin or other contraindicated biguanides: risk of lactic acidosis.
  • IV iodinated contrast in patients with reduced renal function: may precipitate renal failure.
  • Insulin or sulfonylureas: increased risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Cimetidine: may increase metformin plasma concentrations.
  • Diuretics (e.g., thiazides): can affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.

Frequently Asked Questions

Metlinka is prescribed for adult patients with type 2 diabetes mellitus. It is used to improve overall glycaemic control, either as initial therapy or as an add‑on when metformin alone does not achieve target blood‑glucose levels.

Metformin Hydrochloride reduces hepatic glucose output by inhibiting mitochondrial respiration and activates AMP‑activated protein kinase, which improves peripheral insulin sensitivity. This action lowers fasting plasma glucose and contributes to overall glycaemic reduction.

The appropriate dose of Metlinka is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Metlinka in pregnancy and lactation are limited. It should only be used if the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Metlinka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metlinka combines two mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering complementary glucose‑lowering effects. Compared with metformin alone, it provides greater HbA1c reduction, and unlike sulfonylureas it carries a lower intrinsic risk of hypoglycaemia.

Metlinka tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain product stability.

Metlinka is taken orally, usually once daily with a meal, and swallowed whole with a full glass of water. The tablet should not be split, crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, which can be life‑threatening, severe hypoglycaemia when combined with insulin or sulfonylureas, and acute pancreatitis or severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Metlinka is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals taking phenformin or other prohibited biguanides.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT